|
The discovery of FK-506 and U.S. development. |
1991 |
Nephrol News Issues |
pmid:1720512
|
Zheng B et al. |
Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. |
1991 |
Transplant. Proc. |
pmid:1703717
|
Habucky K et al. |
The pharmacodynamics of pentobarbital following FK 506 therapy. |
1991 |
Transplant. Proc. |
pmid:1721282
|
Farghali H et al. |
Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. |
1991 |
Transplant. Proc. |
pmid:1721283
|
Zeevi A et al. |
Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. |
1991 |
Transplant. Proc. |
pmid:1721315
|
Jain AB et al. |
Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. |
1991 |
Transplant. Proc. |
pmid:1721347
|
Perico N et al. |
FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. |
1991 |
Transplant. Proc. |
pmid:1721378
|
Mieles L et al. |
Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. |
1991 |
Transplant. Proc. |
pmid:1703362
|
Wagner K et al. |
Effect of FK 506 on excretion of urinary enzymes in rats. |
1991 |
Transplant. Proc. |
pmid:1721379
|
Warty V et al. |
Distribution of FK 506 in plasma lipoproteins in transplant patients. |
1991 |
Transplant. Proc. |
pmid:1703363
|
Ricordi C et al. |
Human islet allotransplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721410
|
Katayama Y et al. |
Immunosuppressive effects of FK 506 in rat lung transplantation. |
1991 |
Transplant. Proc. |
pmid:1721441
|
Yokomise H et al. |
Immunosuppressive effects of FK 506 in canine lung transplantation. |
1991 |
Transplant. Proc. |
pmid:1721442
|
Tropschug M and Hofmann R |
FK506 and protein kinase C. |
1991 |
Nature |
pmid:1710319
|
Sakai K et al. |
The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. |
1991 |
Brain Res. |
pmid:1723023
|
Haba T et al. |
Pathological and immunohistochemical examination in the rat treated with FK 506. |
1991 |
Transplant. Proc. |
pmid:1714649
|
Forrest MJ et al. |
FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. |
1991 |
Biochem. Pharmacol. |
pmid:1716098
|
Gailliot FP et al. |
Fluidized bed adsorption for whole broth extraction. |
1990 Sep-Oct |
Biotechnol. Prog. |
pmid:1366874
|
Naouri A and Tissot E |
[Indications for liver transplantation in adults]. |
1990 Jun-Jul |
J Chir (Paris) |
pmid:1698800
|
MacLeod AM and Thomson AW |
[FK-506. A new immunosuppressive drug]. |
1990 Jul-Sep |
Medicina (Firenze) |
pmid:1706817
|
Wasik M et al. |
Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. |
1990 Jul-Aug |
Immunopharmacology |
pmid:1699911
|
Morris RE et al. |
Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. |
1990 |
Transplant. Proc. |
pmid:1689885
|
Li PK et al. |
The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. |
1990 |
Adverse Drug React Acute Poisoning Rev |
pmid:1703724
|
Todo S et al. |
Early trials with FK 506 as primary treatment in liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689886
|
McCauley J et al. |
The effects of FK 506 on renal function after liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689887
|
Kang Y et al. |
Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689889
|
Jain AB et al. |
FK 506 dosage in human organ transplantation. |
1990 |
Transplant. Proc. |
pmid:1689890
|
Demetris AJ et al. |
Pathologic observations in human allograft recipients treated with FK 506. |
1990 |
Transplant. Proc. |
pmid:1689891
|
Shapiro R et al. |
The side effects of FK 506 in humans. |
1990 |
Transplant. Proc. |
pmid:1689892
|
Van Thiel DH et al. |
Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689893
|
Woo J et al. |
The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. |
1990 |
Scand. J. Immunol. |
pmid:1690915
|
Yasunami Y et al. |
FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. |
1990 |
Transplantation |
pmid:1691535
|
Metcalfe SM and Richards FM |
Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. |
1990 |
Transplantation |
pmid:1691537
|
Morimoto T et al. |
Pancreaticoduodenal allotransplantation with FK 506 in the dog. |
1990 |
Transplant. Proc. |
pmid:1691550
|
Yasunami Y et al. |
Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. |
1990 |
Transplant. Proc. |
pmid:1691557
|
Thomson AW |
FK-506 enters the clinic. |
1990 |
Immunol. Today |
pmid:1692221
|
Saitoh Y et al. |
Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. |
1990 |
Jpn J Surg |
pmid:1692892
|
Murase N et al. |
Prevention of spontaneous diabetes in BB rats with FK 506. |
1990 |
Lancet |
pmid:1697397
|
Justice RM et al. |
The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. |
1990 |
Biochem. Biophys. Res. Commun. |
pmid:1697463
|
Todo S et al. |
Liver, kidney, and thoracic organ transplantation under FK 506. |
1990 |
Ann. Surg. |
pmid:1697743
|
Sakr MF et al. |
FK 506 ameliorates the hepatic injury associated with ischemia. |
1990 |
Life Sci. |
pmid:1698241
|
Kurasawa K et al. |
The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. |
1990 |
Clin. Immunol. Immunopathol. |
pmid:1698584
|
Miyagawa J et al. |
Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. |
1990 |
Diabetologia |
pmid:1698679
|
Lagodzinski Z et al. |
Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. |
1990 |
Immunology |
pmid:1698713
|
Wilkinson PC and Watson EA |
FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. |
1990 |
Immunology |
pmid:1702750
|
Metcalfe S and Milner J |
Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. |
1990 |
Immunol. Lett. |
pmid:1702753
|
Takada K et al. |
Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. |
1990 |
J. Chromatogr. |
pmid:1703552
|
Woo J et al. |
Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. |
1990 |
Immunology |
pmid:1703987
|
Fung JJ et al. |
Overview of FK506 in transplantation. |
1990 |
Clin Transpl |
pmid:1715740
|
Pugh-Humphreys RG et al. |
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. |
1990 |
Immunology |
pmid:1696242
|